Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Pre-publication versions of this article are available by contacting email@example.com.
|12 Jul 2010||Submitted||Original manuscript|
|26 Jul 2010||Reviewed||Reviewer Report - Jozelio Carvalho|
|17 Aug 2010||Reviewed||Reviewer Report - Cemalettin Aybay|
|8 Sep 2010||Reviewed||Reviewer Report - Patrick Durez|
|8 Nov 2010||Author responded||Author comments - Bart Van den Bemt|
|Resubmission - Version 2|
|8 Nov 2010||Submitted||Manuscript version 2|
|Resubmission - Version 3|
|Submitted||Manuscript version 3|
|17 Nov 2010||Reviewed||Reviewer Report - Jozelio Carvalho|
|24 Nov 2010||Reviewed||Reviewer Report - Cemalettin Aybay|
|12 Jan 2011||Author responded||Author comments - Bart Van den Bemt|
|Resubmission - Version 4|
|12 Jan 2011||Submitted||Manuscript version 4|
|13 Jan 2011||Editorially accepted|
|13 Jan 2011||Article published||10.1186/1471-2474-12-12|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.